A Phase 1 interventional study of avoralstat in Diabetic Macular Edema (DME), sponsored by BioCryst Pharmaceuticals. Terminated at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.
Sponsored by BioCryst Pharmaceuticals · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Macular Edema with a site in Australia — 3 open to participants now, 6 under way, 2 of them phase 3. Macular Edema · Australia.
Among the 36 studies in Macular Edema with a site in Australia, this one is the 36th largest by enrollment, is one of 3 that started in 2025, is one of 4 in phase 1, and was the 35th registered.
758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →3 of the 36 studies in Macular Edema with a site in Australia are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Australia, United States, Argentina and 1 more country
Ages 18+
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) · Sites in Australia, United States, China
Ages 18–65
Kiora Pharmaceuticals, Inc. · Sites in Australia
Ages 18–85
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 22 · Phase 4 2
First in 2004; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 292 across the 36 interventional studies. Of the 30 that completed or were terminated, 24 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 36 have an industry lead sponsor. The 10 most frequent:
BioCryst Pharmaceuticals is the lead sponsor of 54 studies on the registry; 1 is open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.
BioCryst Pharmaceuticals has 1 study filed under Macular Edema — fewer than ten, so there is no comparison to draw.
2 of the studies in Macular Edema with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06825702Kiora Pharmaceuticals, Inc.Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema | 2026-11 |
| NCT05610319McMaster UniversityTreat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies in Macular Edema with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to assess the safety and therapeutic potential of a single dose of avoralstat in adult participants with DME.
Study BCX4161-111 is an open-label, single ascending dose study with 24 weeks follow-up in participants with DME. Three cohorts with a minimum of 3 participants enrolled in each cohort with 3 dose levels of avoralstat (low, medium, high) are planned.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: avoralstat
BCX4161 for suprachoroidal injection
The safety and tolerability of avoralstat in participants with DME. Incidence and severity of ocular (study eye) and systemic treatment emergent adverse events (TEAEs).
Time frame: From screening through EOS (Week 24)
Therapeutic potential of avoralstat in participants with DME. Trends in central subfield thickness (CST) as assessed by spectral domain optical coherence tomography (SD-OCT).
Time frame: From baseline through Weeks 12 and 24
Therapeutic potential of avoralstat in participants with DME. Trends in Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA).
Time frame: From baseline through Weeks 12 and 24
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2025 to primary completion in Apr 2026, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avoralstat